These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19493612)

  • 1. Activin is a potent growth suppressor of epithelial ovarian cancer cells.
    Ramachandran A; Marshall ES; Love DR; Baguley BC; Shelling AN
    Cancer Lett; 2009 Nov; 285(2):157-65. PubMed ID: 19493612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells.
    Steller MD; Shaw TJ; Vanderhyden BC; Ethier JF
    Mol Cancer Res; 2005 Jan; 3(1):50-61. PubMed ID: 15671249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells.
    Ota T; Klausen C; Salamanca MC; Woo HL; Leung PC; Auersperg N
    Differentiation; 2009 Feb; 77(2):162-71. PubMed ID: 19281776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
    Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
    Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell growth regulation through apoptosis by activin in human gastric cancer SNU-16 cell lines.
    Kim YI; Kim BH; Khang I; Cho BN; Lee HK
    Oncol Rep; 2009 Feb; 21(2):491-7. PubMed ID: 19148527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma.
    Ito I; Minegishi T; Fukuda J; Shinozaki H; Auersperg N; Leung PC
    Br J Cancer; 2000 Apr; 82(8):1415-20. PubMed ID: 10780520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
    Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
    Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The autocrine effect of activin A on human ovarian clear cell adenocarcinoma cells.
    Mabuchi Y; Yamoto M; Minami S; Umesaki N
    Oncol Rep; 2006 Aug; 16(2):373-9. PubMed ID: 16820918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.
    Popadiuk CM; Xiong J; Wells MG; Andrews PG; Dankwa K; Hirasawa K; Lake BB; Kao KR
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2216-23. PubMed ID: 16609037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells.
    Rossi MR; Ionov Y; Bakin AV; Cowell JK
    Cancer Genet Cytogenet; 2005 Dec; 163(2):123-9. PubMed ID: 16337854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of hedgehog signaling in ovarian cancer.
    Bhattacharya R; Kwon J; Ali B; Wang E; Patra S; Shridhar V; Mukherjee P
    Clin Cancer Res; 2008 Dec; 14(23):7659-66. PubMed ID: 19047091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activins and activin antagonists in the human ovary and ovarian cancer.
    Reader KL; Gold E
    Mol Cell Endocrinol; 2015 Nov; 415():126-32. PubMed ID: 26277402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions.
    Nanjundan M; Zhang F; Schmandt R; Smith-McCune K; Mills GB
    Oncogene; 2007 Apr; 26(18):2574-84. PubMed ID: 17072347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy.
    Zhang HY; Zhang PN; Sun H
    Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):81-6. PubMed ID: 19540648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.
    Karve TM; Preet A; Sneed R; Salamanca C; Li X; Xu J; Kumar D; Rosen EM; Saha T
    PLoS One; 2012; 7(6):e37697. PubMed ID: 22685544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome.
    Schramm A; von Schuetz V; Christiansen H; Havers W; Papoutsi M; Wilting J; Schweigerer L
    Oncogene; 2005 Jan; 24(4):680-7. PubMed ID: 15580313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of activin A gene by butyrate in human colon cancer cell lines.
    Sonoyama K; Pholnukulkit P; Toyoda M; Rutatip S; Kasai T
    Am J Physiol Gastrointest Liver Physiol; 2003 Jun; 284(6):G989-95. PubMed ID: 12540370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activin A and bone metastasis.
    Leto G
    J Cell Physiol; 2010 Nov; 225(2):302-9. PubMed ID: 20533297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-expression profiling in epithelial ovarian cancer.
    Konstantinopoulos PA; Spentzos D; Cannistra SA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):577-87. PubMed ID: 18648354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
    Badiglian Filho L; Oshima CT; De Oliveira Lima F; De Oliveira Costa H; De Sousa Damião R; Gomes TS; Gonçalves WJ
    Oncol Rep; 2009 Feb; 21(2):313-20. PubMed ID: 19148501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.